Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 24 · below the Ichimoku cloud · RSI 25 (oversold) · MACD below its signal
| 16.45 | 52-week high | +244.14% |
| 7.70 | Previous month high | +61.09% |
| 5.93 | Previous month low | +23.95% |
| 5.75 | Previous week high | +20.29% |
| 5.50 | R3 (classic) | +15.16% |
| 5.15 | Previous week low | +7.74% |
| 5.14 | R2 (classic) | +7.48% |
| 4.84 | R1 (classic) | +1.33% |
| 4.78 | Price now | |
| 4.77 | Previous day high | −0.21% |
| 4.48 | Pivot | −6.35% |
| 4.18 | S1 (classic) | −12.50% |
| 4.11 | Previous day low | −14.04% |
| 4.11 | 52-week low | −14.04% |
| 3.82 | S2 (classic) | −20.18% |
| 3.52 | S3 (classic) | −26.32% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.4M | 0.00% | 191.00K | −5.5% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TRDA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Mpm Bioventures 2014,L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 7.11 - 7.41 per share. | 259.8K | $1.91M |
| Sep 2, 2026 | Mpm Bioventures 2014,L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 7.06 - 7.19 per share. | 86.5K | $617.38K |
| Aug 30, 2026 | Mpm Bioventures 2014,L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 6.99 - 7.20 per share. | 86.9K | $615.78K |
| Aug 25, 2026 | Mpm Bioventures 2014,L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 7.06 - 7.54 per share. | 62.7K | $461.55K |
| Aug 9, 2026 | Parmar Kush MDirector | Sale at price 6.85 - 7.00 per share. | 155.3K | $1.08M |
| Aug 6, 2026 | 5am Ventures V, L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 6.85 - 7.00 per share. | 62.8K | $431.83K |
| Jul 30, 2026 | Parmar Kush MDirector and Beneficial Owner of more than 10% of a Class of Security | Sale at price 6.85 - 6.93 per share. | 116.5K | $807.03K |
| Jul 30, 2026 | 5am Ventures V, L.P.Beneficial Owner of more than 10% of a Class of Security | Sale at price 6.85 - 6.93 per share. | 116.5K | $807.03K |
| May 19, 2026 | Zeiher Bernhardt GDirector | Purchase at price 5.86 per share. | 5K | $29.32K |
| May 3, 2026 | Dowden Nathan JPresident | Conversion of Exercise of derivative security at price 1.74 per share. | 15K | $26.10K |
| May 3, 2026 | Dowden Nathan JPresident | Sale at price 15.33 per share. | 15K | $229.95K |
| May 3, 2026 | Sethuraman NatarajanOfficer | Sale at price 15.39 per share. | 25.9K | $398.81K |
| Mar 31, 2026 | Wentworth Kory JamesChief Financial Officer | Sale at price 12.95 per share. | 2.5K | $32.38K |
| Mar 9, 2026 | Wentworth Kory JamesChief Financial Officer | Sale at price 13.00 - 13.02 per share. | 16.5K | $214.38K |
| Mar 9, 2026 | Dowden Nathan JPresident | Sale at price 13.02 - 13.05 per share. | 15K | $195.77K |
| Mar 3, 2026 | Wentworth Kory JamesChief Financial Officer | Sale at price 12.25 per share. | 8K | $97.89K |
| Feb 26, 2026 | Dowden Nathan JPresident | Stock Award(Grant) at price 0.00 per share. | 55.8K | — |
| Feb 26, 2026 | Sethuraman NatarajanOfficer | Stock Award(Grant) at price 0.00 per share. | 55.8K | — |
| Feb 26, 2026 | Doshi DipalChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 139.4K | — |
| Feb 26, 2026 | Wentworth Kory JamesChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 44.6K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.3 | 4.3 | 5.8 | 7.0 | -47.6 | 4.1 | -7.7 | 3.8 | -9.9 | -24.7 | −53.5% | ||
| 2025 | -22.3 | -11.2 | -24.3 | 1.0 | -16.8 | -11.6 | -12.5 | -7.0 | 6.0 | 19.8 | 47.8 | 0.1 | −40.5% |
| 2024 | -3.4 | -9.2 | 7.1 | -16.4 | 30.5 | -7.9 | 15.6 | 7.5 | -9.7 | 7.3 | 16.0 | -13.1 | +14.6% |
| 2023 | -10.1 | 4.9 | 13.7 | -19.2 | -2.1 | 32.1 | 14.7 | -15.3 | 7.3 | 1.3 | -19.0 | 16.3 | +11.6% |
| 2022 | -35.3 | 9.6 | -22.6 | -36.3 | 13.0 | 80.2 | 5.1 | -1.3 | 24.8 | 44.6 | -34.3 | -9.7 | −21.0% |
| 2021 | 24.3 | -42.5 | −28.5% |
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Buy / hold / sell counts